AstraZeneca PLC (AZN)
| Chiusura precedente | 63,56 |
| Aperto | 63,36 |
| Denaro | 62,64 x 800 |
| Lettera | 62,65 x 900 |
| Min-Max giorno | 62,55 - 63,38 |
| Intervallo di 52 settimane | 52,65 - 72,12 |
| Volume | |
| Media Volume | 5.072.967 |
| Capitalizzazione | 194,69B |
| Beta (5 anni mensile) | 0,23 |
| Rapporto PE (ttm) | 98,01 |
| EPS (ttm) | 0,64 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | 1,45 (2,20%) |
| Data ex dividendo | 11 ago 2022 |
| Stima target 1A | 76,71 |
- GlobeNewswire
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces, following negotiations with the China National Healthcare Security Administration (“NHSA”), ORPATHYS® (savolitinib) has been included in the updated National Reimbursement Drug List (“NRDL”) for the treatment of locally advanced or metastatic non-small cell lung cancer (“NSCLC”) adult patients with MET exon 14-skipping alterations who
- GlobeNewswire
Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology
Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platformCancer genomics testing is now standard practice for cancer care and has shown to be highly successful such as Foundation One (acquired by Roche), Grail (acquired by Illumina), Exact Sciences, Guardant Health and moreExpects ACT to contribute US$25-30 million in revenues in 2023Positions Prenetics solidly within the US$80+ billion global precision oncology ma
- GlobeNewswire
C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programme
C4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and tiered mid-single digit royalties Agreement further substantiates C4XD's scientific expertise and strategy through a third significant deal with a major pharmaceutical company MANCHESTER, United Kingdom, Nov. 28, 2022 (GLOBE NEWSWIRE) -- C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, has signed an exclusive worldwide licensing agreement with
